A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
← catalyst calendarNCT07411560 · readout in 160 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-09 | actual | When the study began enrolling |
| Primary completion | 2027-01-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-26 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obese
Interventions
- Drug: Glucose-dependent Insulinotropic Polypeptide (GIP)
- Drug: Cagrilintide
- Drug: Placebo GIP
Primary outcome
what the primary-completion date above is the date OFNumber of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea
measured From first investigational medicinal products (IMP) administration (visit 2, day 1 or visit 9, day 74) to the end of treatment visit (Visit 2, day 16 or Visit 9, day 89)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed